Bronchitol available to named patients
Tuesday, 17 June, 2008
Pharmaxis (ASX: PXS) will soon be distributing its Bronchitol drug on a named patient basis through UK company IDIS.
Under the arrangement doctors can - through IDIS - prescribe Bronchitol to patients not currently undergoing clinical trials of the drug.
Patients who participate in a named patient program are warned that a drug may have unexpected side-effects, and their doctors are generally indemnified from liability as a result of this disclaimer.
The programs are generally used to allow patients with chronic illnesses access to drugs which can potentially help even in countries where the drug has not yet been cleared for sale. It is particularly used in cases where there is no satisfactory alternative available.
Bronchitol is an inhalant spray aimed at cystic fibrosis and bronchiectasis.
Indigenous-led initiative to resurrect the South Island Giant Moa
New Zealand's Ngāi Tahu Research Centre has partnered with Colossal Biosciences and Sir Peter...
Abnormal brain protein targeted in Parkinson's study
Researchers have identified a new brain protein involved in the development of Parkinson's...
Epilepsy disease model treated in a laboratory dish
A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...
